Shandong Sito Bio-technology Co., Ltd. (SHE:300583)
China · Delayed Price · Currency is CNY 14.13
-0.80 (-5.36%)
Sep 2, 2026, 2:20 PM CST
SHE:300583 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Operating Revenue | 1,105 | 973.52 | 918.22 | 1,225 | 1,242 | 1,174 |
Other Revenue | 17.33 | 43.35 | 52.38 | 54.57 | 70.11 | 28.37 |
| 1,122 | 1,017 | 970.6 | 1,280 | 1,312 | 1,203 | |
Revenue Growth | 23.05% | 4.77% | -24.16% | -2.46% | 9.10% | 31.70% |
Cost of Revenue | 887.08 | 900.66 | 862.5 | 1,011 | 1,051 | 956.55 |
Gross Profit | 234.76 | 116.21 | 108.1 | 268.31 | 261.44 | 246.07 |
Selling, General & Admin | 121.6 | 104.28 | 133.14 | 139.84 | 126.18 | 119.54 |
Research & Development | 40.59 | 41.54 | 58.38 | 55.08 | 50.21 | 49.73 |
Other Operating Expenses | 8.91 | 7.18 | 8.66 | 6.21 | 12.08 | 8.11 |
Operating Expenses | 171.87 | 156.19 | 197.02 | 206.48 | 188.81 | 183.29 |
Operating Income | 62.89 | -39.97 | -88.92 | 61.84 | 72.64 | 62.78 |
Interest Expense | -13.52 | -29.03 | -30.85 | -37.66 | -36.89 | -30.21 |
Interest & Investment Income | 6.31 | 8.35 | 14.76 | 8.35 | 11.71 | 6.63 |
Currency Exchange Gain (Loss) | -0.39 | -1.33 | -0.16 | -1.79 | 0.06 | -0.63 |
Other Non Operating Income (Expenses) | -20.82 | -6.71 | -6.32 | -2.55 | -2 | -1.36 |
EBT Excluding Unusual Items | 34.47 | -68.7 | -111.49 | 28.19 | 45.53 | 37.2 |
Gain (Loss) on Sale of Assets | -0.38 | -0.82 | 0.06 | 0.14 | -0.11 | 0.09 |
Asset Writedown | -17.41 | -12.65 | -0.02 | -0.44 | -0.62 | - |
Other Unusual Items | 4.32 | 5.11 | 8.71 | 25.6 | 3.11 | 17 |
Pretax Income | 21 | -77.06 | -102.75 | 53.48 | 47.91 | 54.29 |
Income Tax Expense | 14.89 | 7.62 | -1.42 | 4.93 | 5.45 | 18.5 |
Earnings From Continuing Operations | 6.11 | -84.68 | -101.33 | 48.55 | 42.47 | 35.79 |
Minority Interest in Earnings | 3.65 | 11.53 | 12.56 | -2.94 | -0.5 | 0.42 |
Net Income | 9.77 | -73.15 | -88.77 | 45.6 | 41.97 | 36.21 |
Net Income to Common | 9.77 | -73.15 | -88.77 | 45.6 | 41.97 | 36.21 |
Net Income Growth | - | - | - | 8.67% | 15.92% | - |
Shares Outstanding (Basic) | 188 | 188 | 189 | 182 | 175 | 170 |
Shares Outstanding (Diluted) | 188 | 188 | 189 | 182 | 175 | 170 |
Shares Change | -0.34% | -0.69% | 3.54% | 4.32% | 2.63% | -0.51% |
EPS (Basic) | 0.05 | -0.39 | -0.47 | 0.25 | 0.24 | 0.21 |
EPS (Diluted) | 0.05 | -0.39 | -0.47 | 0.25 | 0.24 | 0.21 |
EPS Growth | - | - | - | 4.17% | 12.94% | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Jan '23 Jan 1, 2023 | Jan '22 Jan 1, 2022 |
Free Cash Flow | 125.73 | 78.88 | 128.93 | -186.9 | 1.66 | -161.57 |
Free Cash Flow Per Share | 0.67 | 0.42 | 0.68 | -1.02 | 0.01 | -0.95 |
Dividend Per Share | 0.005 | 0.015 | 0.010 | 0.450 | 0.009 | 0.009 |
Dividend Growth | -74.68% | 50.64% | -97.78% | 4687.23% | 0% | - |
Gross Margin | 20.93% | 11.43% | 11.14% | 20.96% | 19.93% | 20.46% |
Operating Margin | 5.61% | -3.93% | -9.16% | 4.83% | 5.54% | 5.22% |
Profit Margin | 0.87% | -7.19% | -9.15% | 3.56% | 3.20% | 3.01% |
Free Cash Flow Margin | 11.21% | 7.76% | 13.28% | -14.60% | 0.13% | -13.44% |
EBITDA | 229.38 | 125.12 | 81.11 | 231.41 | 233.47 | 196.02 |
EBITDA Margin | 20.45% | 12.31% | 8.36% | 18.08% | 17.79% | 16.30% |
D&A For EBITDA | 166.49 | 165.1 | 170.04 | 169.57 | 160.84 | 133.25 |
EBIT | 62.89 | -39.97 | -88.92 | 61.84 | 72.64 | 62.78 |
EBIT Margin | 5.61% | -3.93% | -9.16% | 4.83% | 5.54% | 5.22% |
Effective Tax Rate | 70.89% | - | - | 9.22% | 11.37% | 34.08% |
Revenue as Reported | 509.11 | 1,017 | 970.6 | 1,280 | 1,312 | 1,203 |